Evidence map›Paper›PMID 39229457›Full record

ArticleFrontiers in bioengineering and biotechnology2024

Assessing a single-cell multi-omic analytic platform to characterize

Maryam Moshref, Jerry Hung-Hao Lo, Andrew McKay, Julien Camperi, Joseph Schroer, Norikiyo Ueno, Shu Wang, Saurabh Gulati, Somayeh Tarighat, Steffen Durinck and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Improving resolution with single-cell detection of CRISPR off-target events.Molecular therapy. Methods & clinical development · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maryam MoshrefCell Therapy Engineering and Development, Genentech, South San Francisco, CA, United States.
Jerry Hung-Hao LoOncology Bioinformatics, Genentech, South San Francisco, CA, United States.
Andrew McKayPharma Technical Development Bioinformatics, Genentech, South San Francisco, CA, United States.
Julien CamperiCell Therapy Engineering and Development, Genentech, South San Francisco, CA, United States.
Joseph SchroerCell Therapy Engineering and Development, Genentech, South San Francisco, CA, United States.
Norikiyo UenoCell and Gene Therapy Business Unit, Mission Bio, South San Francisco, CA, United States.
Shu WangBioinformatics Department, Mission Bio, South San Francisco, CA, United States.
Saurabh GulatiBioinformatics Department, Mission Bio, South San Francisco, CA, United States.
Somayeh TarighatCell Therapy Engineering and Development, Genentech, South San Francisco, CA, United States.
Steffen DurinckOncology Bioinformatics, Genentech, South San Francisco, CA, United States.
Ho Young LeeCell Therapy Engineering and Development, Genentech, South San Francisco, CA, United States.
Dayue ChenCell Therapy Engineering and Development, Genentech, South San Francisco, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetically engineered CD8

Indexed as

clustered regularly interspaced short palindromic repeatsengineered CD8+ T cellsfinal cell productheterogeneitymulti-omicssingle-cell

Identifiers

PMID39229457
PMCPMC11368872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.